CD38 and Miyoshi myopathy: By binding to CD38, daratumumab promotes MM-cell apoptosis via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), inhibition of mitochondrial transfer, Fc receptor-mediated cross-linking, and antibody-dependent cellular phagocytosis [175,176].